The association between osimertinib and nutritional deficiency among patients with non-small cell lung cancer.

• DOI: 10.1200/jco.2024.42.16_suppl.8031
• Publication Date: 2024-06-10T19:26:13Z
• Authors: Zhiting Tang; Cho Han Chiang; Yu-Cheng Chang; Xin Ya See; Qian Wang; Afshin Dowlati; Cho Hung Chiang; Kuan-Yu Chi
• Keywords: Osimertinib

8031 Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the standard-of-care in EGFR mutation-positive non-small-cell lung cancer (NSCLC) various settings. Osimertinib commonly causes gastrointestinal adverse effects thereby potentially leading to nutritional deficiencies. Therefore, we aim evaluate association between use of osimertinib and deficiencies among patients with NSCLC. Methods: We performed retrospective, propensity score matched study using TriNetX database, network comprising deidentified data across more than 120 participating healthcare institutions. included NSCLC who received either or other EGFR-TKIs (afatinib, dacomitinib, erlotinib, gefitinib). The outcomes interest vitamin B deficiency, D iron deficiency as well associated anemia including B12 anemia, folate within 5 years EGFR-TKI initiation. Results: 4264 EGFR-TKIs. In Cox proportional hazard analysis, was 50% higher risk (Hazard ratio, 1.52 [95% CI: 1.07-2.16]) compared Consistent this observation, an increased tendency towards anemia. also noted 2-fold 5-fold cohort. Conclusions: anemias One potential explanation extended duration therapy, driven by its potent anti-cancer effects. it advisable consider screening for specific individuals receiving therapy. [Table: see text]